Research Themes
Developmental Projects
New Opportunities
Career Development

Research Themes

Passive Immunotherapeutics
Chair: Arturo Casadevall (Albert Einstein College of Medicine)

Establish and optimize new technologies for producing high affinity animal and humanized neutralizing monoclonal antibodies for passive administration. Identify requirements for antibody-mediated immunity to establish broad principles applicable to multiple systems.

  • Optimization of mAbs to staphylococcal enterotoxin B for treatment: Bettina Fries (Albert Einstein College of Medicine)
  • Development of new passive immunization strategies for anthrax: Arturo Casadevall (Albert Einstein College of Medicine)
  • Development of mAb therapeutics against biothreat and emerging disease agents: Thomas Briese (Columbia University)
  • Development of mAb immunotherapy for genetically modified plague: James Bliska (Stony Brook University)

     Inter-project collaborators

  • Rafi Ahmed (Emory University)
  • Moonsoo Jin (Cornell University)
  • Matteo Porotto (Cornell University)
  • Jeffrey Ravetch (Rockefeller University)
  • Patrick Wilson (University of Chicago)
Chair: John Rose (Yale University)

Establish, characterize and optimize in parallel an array of viral and bacterial vectors as vaccine platforms against biothreat and emerging infectious agents for which vaccines or therapeutics are unavailable.

  • Live recombinant newcastle disease virus as vaccine platform against high priority biodefense pathogens: Peter Palese (Mount Sinai School of Medicine)
  • Development of novel vaccines for high priority pathogens: John Rose (Yale University)
Diagnostic and Pathogen Discovery
Chair: W. Ian Lipkin (Columbia University)
Develop state-of-the-art technologies that permit identification of known and unknown biological agents. Optimize diagnostic technologies to permit widespread clinical availability.
  • Pathogen discovery in emerging infectious diseases: W. Ian Lipkin (Columbia University)
  • Development of a point-of-care platform for differential diagnosis of emerging infectious diseases and biothreat agents: Gustavo Palacios (Columbia University) and Christina Egan (Wadsworth Center)
Chair: Charles Rice (The Rockefeller University)
Explore and target pathogen entry mechanisms and redirected host cell processes for the discovery and development of broad-spectrum anti-infectives.
  • Mechanism and inhibition of dengue and chikungunya virus membrane fusion proteins: Margaret Kielian (Albert Einstein College of Medicine)
  • A novel antiviral platform: untimely activation of viral fusion mechanisms will prevent viral entry: Anne Moscona (Cornell University)
Innate Immunity

Chair: Adolfo Garcia-Sastre (Mount Sinai School of Medicine)

Advance knowledge of the inter-relationship between innate immunity and viral disease outcome. Explore innate immunity pathways as therapeutic targets or enhancers for the treatment of biodefense and emerging disease agents.
  • Filovirus inhibitors of interferon signaling: virulence factors and drug targets: Christopher Basler (Mount Sinai School of Medicine)
  • Inhibition of innate immunity by hemorrhagic fever arboviruses: Adolfo Garcia-Sastre (Mount Sinai School of Medicine)
Microbial Pathogenesis
Chair: Jorge Benach (Stony Brook University)

Discover mechanisms underlying virulence in understudied biodefense pathogens through the use of large-scale molecular and cell biological methods.

  • A genomics based strategy for the discovery and study of new signaling systems and toxins used by relevant bacterial pathogens: Sean Brady (The Rockefeller University)
  • Pathogenic mechanisms of Coxiella burnetti: Craig Roy (Yale University)


Website Design by the : Web Design Studio Site Map